# Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

> **NCT05650229** · PHASE2 · RECRUITING · sponsor: **Abliva AB** · enrollment: 180 (estimated)

## Conditions studied

- Primary Mitochondrial Disease

## Interventions

- **DRUG:** KL1333
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05650229
- **Lead sponsor:** Abliva AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-13
- **Primary completion:** 2027-10
- **Final completion:** 2027-11
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05650229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05650229, "Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05650229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*